A RNA Interference-based Approach to Autosomal Dominant Glanzmann Thrombasthenia: A Step towards Personalized Treatment
ISTH Academy. Bury L. Jul 10, 2019; 274096; OC 72.1 Topic: Platelet Disorders, Hereditary
Dr. Loredana Bury
Dr. Loredana Bury
Access to Reserved content is available to attendees of the Congress until the end of the year and always available for full ISTH members.

Click here to join ISTH or renew your membership.

Discussion Forum (0)
Rate & Comment (0)

OC 72.1

A RNA Interference-based Approach to Autosomal Dominant Glanzmann Thrombasthenia: A Step towards Personalized Treatment

L. Bury, M. Borghi, E. Piselli, P. Gresele
University of Perugia, Department of Medicine, Perugia, Italy

Main Topic: Platelet Disorders
Category: Platelet Disorders, Hereditary

Background: RNA interference (RNAi) is emerging as a promising precision medicine strategy for gene-therapy of dominant negative hereditary disorders acting by suppressing the expression of the dominant mutant gene.
Autosomal dominant Glanzmann Thrombasthenia (GT) is caused by gain-of-function variants of ITGA2B or ITGB3 which generate a constitutively activated αIIbβ3 leading to platelet dysfunction and defective proplatelet formation.
We previously characterized an autosomal-dominant GT with a heterozygous c.2134+1G>C ITGB3 variant leading to the in-frame deletion of exon 13 and to the generation of a c.2015-2134del transcript deriving from exon12-exon14 fusion. The resulting mutant αIIbβ3 exerts a dominant negative effect on normal αIIbβ3, making this gene variant an ideal candidate for a RNAi-based therapeutic approach.
Aims: Aim of this work was to assess whether an allele-specific siRNA can block selectively the synthesis of the dominant negative β3 protein thus restoring the expression and function of αIIbβ3.
Methods: A siRNA molecule (ITGB3bkp12-14 siRNA) targeting the breakpoint region exon12-exon14 was designed. CHO cells expressing wild-type αIIb were transfected using expression vectors with either wild-type or mutant β3 and treated with the ITGB3bkp12-14 siRNA (1-25 nM). The expression of normal and mutant ITGB3 transcripts was assessed by real-time PCR, while expression and function of αIIbβ3 were assessed by flow cytometry.
Results: A ITGB3bkp12-14 siRNA concentration of 7nM efficiently silenced mutant β3 (by 76±17%) without silencing the wild-type transcript (9±2%). CHO cells expressing both normal and mutant αIIbβ3 constitutively bound PAC-1 (which recognizes active αIIbβ3). Treatment with the ITGB3bkp12-14 siRNA abrogated constitutive binding of PAC-1 and restored normal αIIbβ3 activation triggered by DTT, reestablishing normal phenotype.
Conclusions: Our data show that a RNAi-based strategy for gene therapy of autosomal dominant GT is feasible and represents a first step to personalized treatment for this rare disorder.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies